Emkay Global Financial Services maintains its 'Buy' rating on Park Medi World, raising the target price to ₹375 following strong June quarter results, with revenue growth of 19% YoY and profit after tax increasing by 31%. Capacity expands amid risks in government collections.
Emkay Global Financial Services maintains its 'Buy' rating on Park Medi World, raising the target price to ₹375 following strong June quarter results, with revenue growth of 19% YoY and profit after tax increasing by 31%. Capacity expands amid risks in government collections.
<iframe src="https://hindustansphere.com/embed/cluster/07342afa8ee970eef36159d2436d3b3d438f07c4" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Stock to buy after Q1 results 2026: Emkay sees over 32% upside in this healthcare stock"></iframe>
